Kestra Medical Technologies (KMTS) Q1 FY27 earnings call

Kestra Medical Technologies delivered strong Q1 FY27 results, driven by robust revenue growth and significant gross margin expansion, leading to an upward revision of full-year revenue guidance. The company is strategically investing in AI and commercial expansion to enhance operating leverage and rep productivity, aiming for mid-70s gross margins in the coming years. Despite increased losses and cash burn this quarter, management expresses high confidence in its path to profitability, leveraging its differentiated product and expanding WCD market.